Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Investor Presentation (December 2018)
8 slides from Niagen Bioscience's investor presentation, Dec 4, 2018
Slide 1: Investor FAQs Third Quarter 2018
'= ChromaDex ~ Investor FAQs Third Quarter 2018 Nasdaq: CDXC | December 4, 2018
Slide 2: Strategy: FDA approval, new products, retail distribution
Does ChromaDex plan to seek FDA approval for NR as a pharmaceutical? ° ° ° ° STRATEGY We are open to pharmaceutical opportunities for NIAGEN. However, our current strategy is to be a consumer-focused dietary supplement company. Investments in R&D today support a better understanding of NAD and TRU N
Slide 3: Strategy (continued)
iJ = = = B Ff Jefe as stRateGy (continued) @] aq x, , ¢ How many NIAGEN resellers are left? © Westill have a few NIAGEN resellers. e Will you consider selling NIAGEN as an ingredient in the future? © Yes, if the opportunity does not conflict with our strategy of building TRU NIAGEN into a global con
Slide 4: Regulatory
_Boema ten n REGULATORY z | A c af,” eT. © What is the status of regulatory approval in international markets? | fi] o When launching in a new market, three regulatory approvals may be required, £ including: s Go 1 I = Ingredient (NIAGEN); i] iia} = Consumer Products (TRU NIAGEN); and i = Marketing
Slide 5: Science
SCIENCE 4n aS 4 e What placebo-controlled human studies are underway, and what is being measured? a = Oo in o We finished the third quarter with over 160 signed research collaborations. © There are approximately 90 peer-reviewed publications on the science of NR, of which five are s || 1 I human stu
Slide 6: Other FAQs
SP E otuer ai, e Can we expect any NAD testing technology to emerge soon? o NAD testing technology exists today but it is difficult to scale. o We understand the importance of measuring NAD. e Why does a single bottle cost more on truniagen.com than Amazon? o Our current price points were designed t
Slide 7: Appendix A: Preclinical Research and Human Investigations
Preclinical Research More than 100 preclinical peer- reviewed studies have been published investigating the science behind NIAGEN® NIAGEN® has Reached the Significant Milestone of 24 Registered Human Investigations 24 trials are currently registered on clinicaltrials.gov At least 10 more are in plan
Slide 8: Human Studies: Conditions Studied
Human Studies Conditions Studied Neurological, Cardiovascular Health, and Obesity are the Most Prominent Human 4 Clinical Research Areas for NIAGEN® o 31% 28% Parkinson disease Mild cognitive impairment Neuropathies Mild concussion Ataxia telangiectasia 24% 17% Type 2 diabetes U ‘ r Heart failure (I